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Report by the SCC on the use of hydroquinone 
as a skin-bleaching product 
(Opinion expressed 24.2.1983) 
Terms of reference of the Committee 
To give its opinion on the use of hydroquinone in creams and 
lotions for the depigmentation of the skin by local topical 
application in a maximum concentration in the product of 2%. 
Conclusion 
In view of the hazard presented by other depigmenting agents, 
the Committee agrees to the use of hydroquinone at concentra-
tions not exceeding 2 % in cosmetic products for the depig-
mentation of localized melanotic areas, provided that the 
usual precautions are fully indicated on the label 
(see item 1 4 ) . 
Background 
1. Council Directive 76/768/EEC on the approximation of the 
laws of the Member States relating to cosmetic products, 
as last amended by Directive 82/368/EEC, authorizes 
hydroquinone only as an oxidation colouring agent 
for the colouring of hair in a maximum concentration 
of 2% in the final cosmetic product (Annex III, first 
part, number 1 4 ) . 
2. The use of hydroquinone as a skin-bleaching product is 
outside the scope of the Directive mentioned (Annex V ) , 
i.e. the Member States can make any provision they 
see fit in respect of this use. 
3. Nevertheless, the Council has invited the Commission to 
examine hydroquinone to see whether it could be admitted 
at Community level for uses other than hair colouring. 
4 . T h u s , t h e C o m m i t t e e i s i n v i t e d t o g i v e an o p i n i o n on t h e 
use o f h y d r o q u i n o n e i n c reams and l o t i o n s f o r t h e d e p i g m e n -
t a t i o n o f t h e s k i n by l o c a l t o p i c a l a p p l i c a t i o n i n a 
maximum c o n c e n t r a t i o n o f 2% i n t h e f i n a l c o s m e t i c p r o d u c t . 
D i s c u s s i o n 
5 . The acute t o x i c i t y t e s t s c a r r i e d out i n severa l animal spec ies , us ing 
var ious routes of a d m i n i s t r a t i o n , have shown t h a t hydroquinone i s Less 
t o x i c when g iven dermal ly ( L D , . - > 900 mg/kg) than when g iven o r a l l y 
(LDc-p. about 350 mg/kg ) , i n t r a v e n o u s l y , i n t r a p e r i t o n e a l l y or subcutaneously 
(LD,-n about 170 mg/kg ) . (F igures de r i ved from exper iments on r a t s . ) 
6 . When a p p l i e d i n a 5 % aqueous s o l u t i o n , hydroquinone does not i r r i t a t e the 
r a b b i t e y e . I t proved t o be s l i g h t l y i r r i t a n t t o r a b b i t s k i n when 
app l i ed under o c c l u s i o n at a 4 .6 % concen t ra t i on i n a cream. I n man, 
du r ing depigment ing t r e a t m e n t s , i r r i t a n t e f f e c t s on the sk i n were observed 
when concen t ra t i ons h igher than 4 %, were used. 
7 . Two max imizat ion t e s t s i n gu inea-p igs d i sc l osed no s e n s i t i z i n g p r o p e r t y . 
8 . Hydroquinone i s s low ly absorbed through the human sk i n and i s r a p i d l y 
e l i m i n a t e d i n the faeces and u r i n e . 
9 . In a s h o r t - t e r m t o x i c i t y study (63 days) and i n a medium-term t o x i c i t y 
study (6 months) i n v o l v i n g o r a l a d m i n i s t r a t i o n o f h igh doses i n r a t s , 
the f o l l o w i n g observa t ions were made : e f f e c t s on the bone marrow, changes 
i n the blood p i c t u r e , loss of body weight and dys t r oph i c changes i n 
severa l o rgans , e s p e c i a l l y the l i v e r , the kidney and the myocardium. 
The no e f f e c t l e v e l was assessed as 0.5 mg/kg b .w. /day i n r a t s . The t a r g e t 
organs were the same i n a s h o r t - t e r m t o x i c i t y study (50 days) us ing 
the percutaneous rou te i n g u i n e a - p i g s , but the a b o r m a l i t i e s observed 
depended more on the sur face area t r e a t e d than on the c o n c e n t r a t i o n 
of hydroquinone employed. In a d d i t i o n , neuro-motor e f f e c t s have been 
observed i n severa l s h o r t - t e r m t o x i c i t y s tud ies i n v o l v i n g o r a l and 
subcutaneous a d m i n i s t r a t i o n , i n p a r t i c u l a r i n c a t s , mice and r a t s . 
10. No a b n o r m a l i t i e s were observed i n new-Horn animals du r i ng a 
t e r a t o g e n i c i t y study i n v o l v i n g dermal a p p l i c a t i o n t o female r a t s of 
doses of up t o 810 mg/kg b .w . /day . 
Reproduction Studies, after oral administration in rats, disclosed 
no foetal abnormalities, but in one of the studies, the number of cases 
of foetal resorption was greater in the treated animals. 
11. Results of mutagenicity tests were inconsistent. 
12. Long-term oral studies in rats and dogs showed no carcinogenic effect; 
furthermore, two studies carried out on mouse skin demonstrated an 
absence of cocarcinogenic action or of any cancer-inducing action. 
13. Industrial exposure in man can give rise to conjunctival and corneal 
irritation and pigmentation. When the product was used extensively 
and continuously by Bantu women, cases of deterioration of 
connective tissue were noted. 
14. Insofar as products containing hydroquinone intended as topically 
applied skin-depigmenting agents are regarded as cosmetic products, 
within the meaning of Directive 76/768/EEC, the Committee, considering 
both the dager represented by other depigmenting agents and the 
toxicological data, concludes that, owing to the relative safety of 
the substance in use, it is able to agree to the incorporation of 
hydroquinone at concentrations of not more than 2 % in cosmetics for 
the depigmentation of localized melanotic areas, provided the following 
precautions are indicated on the labels : 
- must be used with a sun-screen product; 
- must not be used for more than two months; 
- must not be used near the eyes; 
- must not be used on children under twelve; 
- stop using if there is any irritation; 
- depigmenting effect is low on black skin. 
Ref. : COLIPA file 
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REPORT BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
ON THE USE OF SILVER NITRATE IN COSMETIC PRODUCTS 
FOR DYEING EYELASHES AND EYEBROWS 
(Opinion expressed 26 May 1983) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give its opinion on the use of silver nitrate in cosmetic products for 
dyeing eyelashes and eyebrows with a maximum concentration of 4 % in the 
finished cosmetic product. 
CONCLUSION 
The Committee can accept the use of silver nitrate in cosmetic products 
for dyeing eyelashes and eyebrows under the conditions in 
Directive 76/768/EEC. 
BACKGROUND 
1. Pursuant to Article 5 of Directive 76/768/EEC on the approximation of 
the laws of the Member States relating to cosmetic products, as last 
amended by Directive 83/191/EEC, the Member States must accept, up 
to 31 December 1985, the marketing of cosmetic products containing 
silver nitrate subject to the following restrictions and conditions : 
- field of application and/or use : solely for products intended to dye 
eyelashes and eyebrows; 
- maximum authorized concentration in the finished cosmetic 
product : 4 %; 
- conditions of use and warnings which must be printed on the label : 
Contains silver nitrate. 
Rinse eyes immediately if product comes into 
contact with them. 
2. On expiry of that period, silver nitrate will be : 
- either definitively permitted (Annex III); 
- or definitively prohibited (Annex II); 
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- or retained for a given period in Annex IV; 
- or deleted from all annexes. 
3. Consequently the Committee is asked to deliver an opinion on the use of 
silver nitrate in cosmetic products subject to the abovementioned 
restrictions and conditions. 
DISCUSSION 
4. In the cosmetology department of Göttingen University, a clinical test has 
been carried out by estheticians on 380 women aged from 18 to 62, by 
applying to the eyelashes a product containing a 2.8 % concentration of 
si Iver nitrate. 
5. The desired colouring effect is obtained after a period varying from 40 
to 180 minutes. 
6. At periods of from three to eight weeks after the application, no 
irritation or allergy, or fragility of the eyelashes, was observed. 
7. For treatment purposes, AgNO., is used in a concentration of 1 % for 
gingivitis and injuries in newborn infants. 
8. Oral intake of AgNO., can cause problems resulting from argyria but 
cutaneous absorption is naturally limited by a self-regulating mechanism 
of the skin. The AgNO., is precipitated in the form of metallic silver 
by the skin proteins. 
9. In view of the good skin tolerance and absence of cutaneous absorption 
of AgNO,, the Committee concludes that it can accept the use of 
AgNO, for dyeing eyelashes and eyebrows under the conditions laid down 
in the Directive on cosmetic products. 
REPORT BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
ON THE USE OF SELENIUM DISULPHIDE IN SHAMPOOS 
(Opinion expressed 20 September 1983) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give its opinion on the use of selenium disulphide in shampoos at 
a maximum concentration of 1 % in the finished cosmetic product. 
CONCLUSION 
The Committee can accept the use of selenium disulphide in shampoos at 
a maximum concentration of 1 % in the finished cosmetic product. 
BACKGROUND 
1. Council Directive 76/768/EEC on the approximation of the laws of the 
Member States relating to cosmetic products, as last amended by 
Directive 83/341/EEC , prohibits under Article 4 the marketing of cos-
metic products containing selenium and selenium compounds (substance 
297 in Annex II). 
2. The industry has requested that an exception be made in the case of 
selenium disulphide in shampoos in view of the valuable anti-
dundruff properties of this compound. 
3. Consequently, the Committee is requested to give an opinion on the 
use of selenium disulphide in shampoos with a maximum content of 1 % 
in the final cosmetic product. 
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DISCUSSION 
4. The acute toxicity of selenium disulphide administered orally to rats, 
mice and rabbits varies considerably from one study to another (LD^ of 
62 to 200 mg/kg b.w. in some studies and 490 to 3690 mg/kg b.w. in others). 
5. At a concentration of 2.5 % in a shampoo, selenium disulphide has a 
slightly irritant effect on the intact or abraded skin of rabbits. 
With repeated application of a 1 % shampoo, reversible erythema and 
edema are observed at the point of application. 
6. Selenium disulphide is well tolerated by the rabbit eye at a 
concentration of 0.5 % in an ointment; it is irritating at 1 % in an 
ointment and at 2.5 % in a shampoo. 
7. A study of oral uptake in mice shows that selenium is concentrated in 
the blood, liver and kidneys from doses of 125 mg selenium disulphide 
per kg body weight upwards. With percutaneous application in mice, 
penetration is slight (about 1 % of the dose applied). 
In man, data on percutaneous absorption disagree and are possibly 
influenced by the fluctuations in the normal daily absorption of selenium. 
8. In short-term toxicity studies of oral administration in rats and mice, 
degeneration of the liver and kidneys is observed. The first anomalies 
are observed at a dose of 31.6 mg of selenium disulphide per kg body weight, 
With dermal application,short-term studies in mice reveal, in addition 
to the local effects observed at all doses (erythema -* edema -*■ acanthosis-
hyperkeratosis), a systemic effect on the liver and kidneys (hepatic 
necrosis and interstitial nephritis), the no-effect dose being estimated 
at 1 mg of selenium disulphide per kg b.w. per day. 
9. In long-term studies, oral administration of doses of selenium disulphide 
of about 15 mg/kg body weight in rats and 100 mg/kg body weight in mice 
brings about a significant increase in hepatic tumours (hepatocellular 
carcinoma and adenoma) and in the female mouse an increase in the 
number of alveolar and bronchiolar tumours is observed. 
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This finding of carcinogenic activity after oral administration 
reinforces the biological significance of the long-term tests carried 
out by dermal application in mice, even though in this case the 
incidence of the increase in tumours in the target organs is not 
signifi cant. 
10. From a considerable number of recent experiments in mice and rats it 
appeared that increased ingestion of selenium may result in a 
significant reduction of both chemically induced and spontaneous mammary 
tumours. Moreover, indications have been obtained that administration 
of additional selenium may lengthen the latency period of mammary tumours 
and may decrease the number of these tumours per tumour-bearing animal. 
These findings suggest that selenium possesses anti-carcinogenic properties. 
11. Bearing in mind the level of the doses having a carcinogenic effect in 
animals, the fact that selenium is an essential element in the human body, 
the system for the regulation of blood selenium in man, the low 
percutaneous absorption and bearing in mind also that selenium has an 
anti-carcinogenic effect, the Scientific Committee on Cosmetology concludes 
that the carcinogenic risk for man is negligible and that it can accept 
the use of selenium disulphide at a concentration of 1 % in shampoos. 
REPORT BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
ON THE USE OF BENZOYL PEROXIDE IN COSMETIC PRODUCTS 
(Opinion expressed 29 November 1983) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give its opinion on the use of benzoyl peroxide in lotions, creams and 
gels for greasy skin in a maximum concentration of 3% in the finished 
cosmetic product, provided that the following warnings appear on the label : 
- Contains benzoyl peroxide 
- Avoid all contact with the eyes and mouth 
- Discontinue use if irritation occurs 
- Do not use simultaneously with other cosmetic products. 
CONCLUSION 
The Committee can agree to the use of benzoyl peroxide in cosmetic products 
in a maximum concentration of 3% in the finished cosmetic product, subject 
to the above-mentioned warnings. It recommends that the following warning 
be added thereto : "Do not expose yourself to sunlight immediately after 
applying the product !" 
BACKGROUND 
1. Article 12 of Directive 76/768/EEC on the approximation of the laws of 
the Member States relating to cosmetic products, as last amended by 
Directive 83/574/EEC, provisionally allows each Member State to prohibit 
or to subject to special conditions on its territory the placing on the 
market of a cosmetic product if it notes, on the basis of a detailed 
statement of reasons, that that product, although complying with the 
requirements of the Directive, represents a hazard to health. 
2. On the basis of that Article, a Member State has prohibited the use of 
benzoyl peroxide in cosmetic products in view of the irritant and 
sensitizing properties of that substance. 
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3. Consequently, the Committee was requested to deliver an opinion on 
the use of benzoyl peroxide in cosmetic products under the conditions 
envisaged. 
DISCUSSION 
4. Acute toxicity in rodents is not severe. The oral LD,-n in rats is 
higher than 5 000 mg/kg. 
5. Cosmetic preparations containing 5 to 10% concentrations of benzoyl peroxide 
irritate rabbits' skin. The severity of the irritation depends on the 
duration of exposure and the quantity applied. 
At the same concentrations in cosmetic creams, lotions and gels, 
applied with or without rinsing, the substance has a slight to severe 
irritant effect on rabbits* eyes. 
6. The results of the phototoxicity tests in guinea-pigs are equivocal 
A 5% benzoyl peroxide cream produces a phototoxic effect whereas a 
5% lotion exerts no effect. 
7. In a sensitization study in guinea-pigs, a sensitizing effect was 
observed with a preparation containing 10% of benzoyl peroxide and 
1% of sulphur. 
8. Dermal studies of metabolism in rats and monkeys showed that benzoyl 
peroxide penetrates the skin by being converted into benzoic acid which 
is excreted in the urine, chiefly in the form of hippuric acid. 
9. The short-term (three months) oral toxicity studies in rats revealed, 
at a 2g/kg b.w. intake, effects on the kidneys in particular, as well as 
loss of weight, general weakness and intermittent irritability. 
10. A short-term (thirteen weeks) toxicity study in rats involving cutaneous 
application of a 3.2g/kg preparation containing 5% of benzoyl peroxide 
produced irritant effects on the skin and the following systemic 
effects : retarded growth, reduction of serum aspartate aminotransferase 
and of spleen weight, together with increase in blood urea nitrogen and 
kidney weight. 
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11. Several long-term studies in rats and mice, in which benzoyl peroxide 
was applied alone, showed no carcinogenic effect; in one oral study 
in rats, testicular atrophy was observed at all doses (28.26 to 2826 mg 
of benzoyl peroxide in the diet) as a result of vitamin E deficiency. 
12. In a one-year study involving dermal application to mice, benzoyl peroxide 
caused papillomata and spinocellular epitheliomata, after initiation 
with 7,4-dimethylbenzanthracene,at all doses (1 to 40 mg of benzoyl 
peroxide in acetone, two applications per week). This effect was not 
reproduced in another breed of mice after initiation with U.V.B. 
irradiation, but this study was scarcely significant; it was prematurely 
broken off after 62 weeks. 
13. In man, in spite of the high percentage of sensitization (40 to 70) 
observed during maximization tests, the clinical experience of 
dermatologists revealed that the incidence of allergic reactions in 
patients treated for acne with benzoyl peroxide was less than 1%. 
In the USA, where benzoyl peroxide, classified as an over-the-counter 
product, is extensively used, the experience of the FDA and of companies 
belonging to the EPA suggests that the level of sensitization 
corresponding to widespread use of benzoyl peroxide in cosmetics is 
between 0.004 and 0.5%. Benzoyl peroxide is unquestionably a primary 
irritant (17% of cases of primary irritation dermatitis at the 
beginning of acne treatment). 
Clinical studies in man have not revealed any cases of skin cancer 
(124 patients over nine years) or any systemic effect, except for one 
case of anaphylactic systemic reaction. 
14. The Committee concludes that, apart from its irritant effect on the skin, 
benzoyl peroxide has the same safety potential as cosmetic ingredients 
in general and that it can approve its use, in a 3% concentration, in 
cosmetic products, subject to the labelling recommendations envisaged. 
It is advisable to add to the latter that of not exposing oneself to 
sunlight after application of the product. 
Nevertheless, several members consider that this substance should be used 
solely under medical supervision and the Committee reserves the right to 
review this opinion in the light of the new clinical studies being 
conducted in the Federal Republic of Germany on the variation in the 
threshold of the sensitivity of the skin to U.V.B. radiation after 
short-term application of a preparation containing 3% of benzoyl peroxide. 
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REPORT 
BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
CONCERNING THE USE OF NICOMETHANOL HYDROFLUORIDE 
IN ORAL HYGIENE PRODUCTS 
(Opinion expressed 29 November 1983) 
TERMS OF REFERENCE OF THE COMMITTEE 
To express its opinion on the use of nicomethanol hydrofluoride in oral 
hygiene products in a maximum concentration in the finished product of 
0.15% expressed as fluorine. 
CONCLUSION 
The Committee can agree to the use of nicomethanol hydrofluoride in 
oral hygiene products in accordance with the conditions set out in 
paragraph 2. 
HISTORICAL BACKGROUND 
1. Directive 76/768/EEC, as last amended by directive 83/574/EEC, authorizes 
the use in oral hygiene products of a number of fluorine compounds in a 
maximum concentration of 0.15%, calculated as F, in the finished 
cosmetic product, subjet to certain conditions of use and warnings which 
must be printed on the label. The Commission had received a request 
for the addition of nicomethanol hydrofluoride to the list of fluorine 
compounds already allowed. According to the dossier submitted by the 
manufacturer, nicomethanol hydrofluoride offers a particular 
advantage as regards fluorine fixation on dental enamel, while 
being free of any toxicity under normal conditions of use. 
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2. Consequently, the Committee was requested to express an opinion on the 
use of nicomethanol hydrofluoride in cosmetic products, subject to the 

































Conditions of use 
and warnings which 
must be printed 





3. Nicomethanol hydrofluoride is more toxic when administered intraperitoneally 
than when given orally in rats and mice. The oral LD,-n is approximately 
500 mg/kg in rats and mice; expressed as fluorine ions (i.e. approximately 
75 mg/kg), the LD-., is comparable to that of tin fluoride and slightly 
greater than that of sodium fluoride. The product is emetic in dogs. 
The acute toxicity of the organic carrier of the fluorine, namely 
nicotinic alcohol, is distinctly lower than that of fluorine, being 
above 5 g/kg when given orally and above 2 g/kg when the intraperitoneal 
route is used in mice. 
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4. When applied in a 6.8% aqueous solution, nicomethanol hydrofluoride has 
no irritant effect on rabbits' eyes and it is well tolerated by the 
mucous membranes of hamsters' cheek pouches. No bleeding of the digestive 
nucosae was observed in mice after oral ingestion of doses of 68 mg/kg b.w. 
dai ly. 
5. A Magnusson and Kligman maximization test using both the intradermal 
and the epidermal route with weak dilutions corresponding to the maximum 
non-irritant concentrations (0.04% intradermally and 0.2% epidermally) 
revealed no sensitizing effect. 
6. The 60-day oral toxicity study in dogs was not carried out with a 
sufficiently high dose (34 mg/kg b.w. daily) for any effect to be observed 
by means of the usual macroscopic, histological and biochemical examinations, 
hence it was not possible to determine the no-effect level. 
7. A "long-term" oral study in rats at doses of 10.2, 34 and 102 mg/kg b.w. 
daily, which was broken off after seven months of trials, revealed the 
usual signs of luorosis in the teeth and in the long and flat bones at 
upwards of 34 mg/kg b.w. daily and a slight slowing of growth at the 
highest dose. (The Committee regrets that the study was not carried out 
in such a way as to enable any risk of carcinogenesis to be determined 
experimentally.) 
8. Mutagenicity studies were carried out : 
1. Using bacteria (Salmonella typhimurium) in an Amestest with and 
without added liver enzymes. 
2. Using orally treated mice in a micronucleus test. 
The Amestest produced negative results but the micronucleus test was 
inconclusive due to the inadequacy of the protocol used. 
The Committee could not make an evaluation of the mutagenic potential 
of this compound on the basis of the data provided. 
9. When administered in doses of about 150 to 300 mg daily, nicotinic alcohol 
has a vasodilator and hypolipaemic action. Its metabolism is well known; 
its principal metabolite, nicotinic acid, to which the hypolipaemic 
effect is due, is transformed in vivo into nicotinic amide (vitamin PP). 
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10. Undesirable effects (reddening, giddiness and liver function disorders) 
have been reported after absorption of high doses of nicomethanol and 
nicotinic acid. 
11. In conclusion, the Committee considers that the quality of some of 
the studies contained in the dossier is not entirely satisfactory. 
It notes, however, that : 
. the chronic toxicity at high doses of nicomethanol hydrofluoride 
is that of the fluorine ion; 
. although the long-term studies were not continued, there is 
nothing in the available information to suggest carcinogenic 
hazard; 
. the pharmacological activity and the untoward effects reported 
for nicotinic alcohol do not manifest themselves under normal 
conditions of use unless the doses are at least 120 times (G.Zbinden) 
those which could be ingested when used normally in toothpaste; 
. the final metabolite of nicomethanol is a vitamin normally found 
in all foods, especially in meat and cereals. 
12. Consequently, the Committee considers that nicomethanol hydrofluoride 
is not dangerous when used in oral hygiene products in the concentration 
applied for and recommends that it be added to the list of fluorinated 
compounds already allowed. 
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Scientific Committee on Cosmetology 
Supplementary opinion concerning the use of 1,1,1-trichloroethane 
(methy Ichloroform) in cosmetic products 
(Opinion expressed on 22 May 1984) 
(1 ) Pursuant to point 7 of the opinion which it expressed on 25 September 1979 , 
the Committee examined the fresh items of information brought to its notice. 
1. Stabilizers of 1,1,1-tri eh loroethane (TCE) are mixtures, generally patented, 
of widely differing compositions, among which are to be found carcinogenic 
substances such as epich lorohydrin and 1,4-dioxane. 
From most of the reports on toxicity studies now available, nothing can be 
inferred regarding the degree of purity of 1,1,1-trich loroethane and the 
nature of the stabi lizers used. 
2. Quantitative determinations carried out over a period of three weeks on 
F 11, F 12, dich loromethane, isobutane and propane in a hairdressing saloon 
showed that the maximum concentrations of each of these propel lants in the 
saloon air did not exceed 50 ppm by volume and were therefore considerably 
lower than the threshold limit values (TLV) specified for each of them. 
1,1,1-Trich loroethane, which was not included in this study but whose 
physico-chemical properties are fairly close to those of dichloromethane, 
can be put in the same category as the latter. 
3. In the chronic inhalation toxicity studies no effects were observed in the 
rats, mice and dogs which were continuously exposed to 250 and 1 000 ppm of 
1 ,1 ,1-t ri c h lo roe t h an e. 
(1) EUR Report No 7297 
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4. In an in vitro Ames mutagenicity test with metabolic activation, no 
mutagenic effect was observed, whereas another test, performed according to 
the same protocol, showed slight mutagenic activity with and without 
metabolic activation. The purity of the 1,1,1-trichloroethane samples used 
in these tests was unknown and it can be assumed that the stabilizer was 
responsible for the positive result obtained in the second test. 
A dominant lethal test in mice, with administration in the drinking water, 
produced a negative result with concentrations of up to 100 mg/kg. 
5. In the three acute in vitro morphology transformation tests carried out on 
rat embryo cells, SA 7 adenovirus and Syrian hamster embryo cells, an 
increase in the number of cases of cell transformation was observed which, 
in the latter two tests, depended on the dose. Although the information 
supplied by the manufacturer indicates the presence of a 3% concentration of 
1,4-dioxane in these two cases, it was not possible to identify this 
compound by chemical analysis and it was the non-carcinogenic substance 2-
methy l-2-butanol which was detected. 
6. An inhalation carcinogenicity study with 875 and 1 750 ppm concentrations in 
rats, which was unfortunately too short (twelve months), showed no increase 
in the incidence of tumours in these animals when observed for a period of 
30 months. 
7. In oral carcinogenicity studies carried out by the NCI, the doses 
administered by gavage were 3 000 and 6 000 mg/kg/day for mice and 750 and 
1 500 mg/kg/dag for rats. The survival rate was low both in the rat and in 
the mouse study. 
In the high dose group 3 out of 49 male mice had hepatocellular adenomata 
and one had a hepatocellular carcinoma. No tumours were observed in the 
control group of mice. In the rat study no increase in incidence of tumours 
was observed. 
It should be noted that the 1,1,1-trich loroethane used contained 3% 
1,4-dioxane, which means that the group of mice treated with the highest 
dose received 120-180 mg 1,4-dioxane/kg daily. 
Owing to the low survival rate, the NCI has repeated an oral carcinogenicity 
investigation in rats and mice with pure 1,1,1-trich loroethane, but the 
results are not yet to hand. 
- 17 
8. On the basis of the available reports on carcinogenicity studies, the 
International Agency for Research on Cancer (IARC) has concluded that the 
results are at present inadequate for assessing the carcinogenic potential 
of 1,1,1-trich loroethane. 
9. In man, immersion for 30 minutes in a bath containing 1,1,1-trichloroethane 
showed that this product penetrates the skin, enters the bloodstream and is 
excreted for the most part via the air passages. 
In workers exposed to airborne TCE in their workshops, a high concentration 
(50 to 70%) was observed in the alveolar air 30 minutes after exposure, 
while only a small quantitiy was metabolized into trich loroethanol (2%) and 
trichloroacetic acid (0.5%), both of which were excreted in the urine. 
The half-life of 1,1,1-trich loroethane, calculated on the basis of the 
elimination of these two metabolites, was estimated at 8.7 hours. 
10. Again in man, the first appearance of functional CNS depression was at 
500 ppm, at which concentration a sedative effect was observed; the first 
anaesthetic effect occurred at 1 000 ppm. 
Exposure to concentrations of 5 000 to 20 000 ppm caused coordination loss 
and anaesthesia. Sudden death due to ventricular fibrillation and 
respiratory standstill can occur at the anaesthetic concentrations. 
In cases of acute poisoning, a hepatotoxic effect was observed. 
11. In a large-scale study with workers exposed to 1,1,1-trichloroethane over 
six years, no signs of cardiotoxicity or chronic hepatotoxicity were 
observed. No information about carcinogenicity is available. 
12. The Committee has decided to await the outcome of the new ongoing 
carcinogenicity studies by the NCI before expressing a definitive opinion 
on 1,1,1-trichloroethane. 
In the meantime, the Committee hopes to obtain further information on the 
purity of the 1,1,1-trichloroethane and also on the nature of the 
stabilizers used, since it appears that the industry is endeavouring to 
replace stabilizers that are reputed to be toxic by well-known substances 
which are less toxic or by new substances of which little is known 
concerning toxicity. 
- 18 
Report by the Scientific Committee on Cosmetology 
concerning certain zirconium complexes used 
in antiperspirants 
(Opinion expressed 22 May 1984) 
TERMS OF REFERENCE OF THE COMMITTEE 
To express its opinion on the use as antiperspirants of aluminium 
zirconium chloride hydroxide complexes and the aluminium zirconium 
chloride hydroxide glycine complex at a maximum concentration in the 
finished cosmetic product of 20% expressed as anhydrous hydroxychloride 
and of 5.4% expressed as zirconium. 
CONCLUSIONS 
The Committee is able to approve the use of zirconium complexes as 
antiperspirants, subject to the conditions and restrictions set out in 
paragraph 1, provided that labelling of the finished product includes the 
warning : Do not apply to irritated skin. 
HISTORICAL BACKGROUND 
1. In accordance with Article 5 of Directive 76/768/EEC on the 
approximation of the laws of the Member States relating to cosmetic 
products, as last amended by Directive 83/574/EEC, the Member States 
must, until 31 December 1985, permit the marketing of cosmetic products 
containing aluminium zirconium chloride hydroxide complexes and 
glycine, subject to the following conditions : 
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1 RESTRICTIONS 
Substance Field of Maximum authorized Other limitations 
application concentration in and requirements 
and/or use the finished cos­
metic product 
Aluminium zi ι— Anti perspi rants 20% as anhydrous 1. The ratio of the 
conium chloride aluminium zircon- number of aluminium 
hydroxide com- ium chloride hy- atoms to that of 
plexes droxide zirconium atoms must 
i be between 2 and 10 
Al Zr(OH) Cl 5.4% as zirconium 
2. The ratio of the 
and the alumi- number of (Al+Zr) 
nium zirconium atoms to that of 
chloride hy- chlorine atoms must 
droxide glycine be between 0.9 and 
complex 2.1 
3. Prohibited in aero­
sol dispensers 
(sprays) 
2. Beyond this deadline, such substances shall be : 
authorized definitively (Annex III); 
or prohibited definitively (Annex II); 
or authorized during a period laid down in Annex IV; 
or deleted from all the annexes. 
3. The Committee has therefore been invited to express an opinion on the 
use of certain aluminium zirconium chloride hydroxide complexes and the 
aluminium zirconium chloride hydroxide glycine complex, subject to the 
abovementioned limits and conditions. 
DISCUSSION 
4. Chemical formula and structure 
Al Zr (OH) Cl .nH_0.Z(NH_-CH-,C00H) v w χ y 2 2 2 
Complexe 
tri Al 3.3' 
Empi r i ca l formulae 
Z r (0H) 1 1 CL2 6 , nH20,z (NH^CH -C00H) 
20 
tetra Al , ,, Zr(OH)_ ,, Cl, 01 nH_.0,z (NH--CH -COOH) j.O II.6 j.ti ά c ¿ 
penta Al. cl Zr(0H)„ .,, CI. -,, nH_0,z (NH_.-CH_,-C00H) 
octo Al 7 , Zr(0H)19 g, Cl? , nH20,z (NH--CH -COOH) 
5. LD,-n is 400-700 mg/kg by the dermal route in rabbits and 
2 420-6 930 mg/kg by the oral route in rats. 
6. Studied at various concentrations (9.7%, 15.9%, 22.5%), ZAG is not 
considered as an irritant on rabbits' eyes although some studies 
demonstrate a slight but reversible irritation. 
7. In a series of studies in rabbits, at concentrations of 9.7%, 22.5%, 
35% and 50%, ZAG had a non-irritant to slightly irritating effect on 
intact and abraded skin, with and without occlusion. 
8. In a 28-day study in rabbits, a 34.7% solution of ZAG was applied to 
the skin at a rate of 2 ml/kg bw. The treated animals did not differ 
significantly from the control group as regards body weight, clinical 
symptoms, haematology and macroscopic and microscopic anatomopathology. 
In a 91-day study involving application of a 34.7% solution of ZAG to 
the intact skin of rabbits (2 ml/kg bw), slight erythema was observed, 
in addition to histological and haematological changes, a reduction in 
the weight of the liver and an increase in the weight of the suprarenal 
glands and ovaries, all statistically insignificant and therefore 
considered of no biological significance. 
The same effects are observed in parallel studies involving finished 
products containing 19.9% and 20% of ZAG, respectively. The 
histopathological evaluation indicates slight acanthosis, practically 
without any dermal papillary inflammation - the only change considered 
si gni ficant. 
9. ZAG does not induce dominant lethal mutations when administered orally 
to mice at doses of 40, 400 and 4 000 mg/kg over a period of five days. 
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10. No teratogenic effects were observed following dermal administration of 
a 31.5% solution of ZAG to rabbits between the 7th and 18th days of 
gestation at maximum doses of 2 000 mg/kg/day. 
11. The available data, derived from several studies of ZAG, 
Zr hydrochloride, Al hydrochloride and NaZr lactate, indicate that 
under extreme experimental conditions ZAG can induce delayed 
hypersensitization reactions; such effects are limited and temporary. 
Intradermal injection of 0.1 ml of a saline solution containing 0.05 mg 
ZAG in guinea pigs and 0.1 ml of a saline solution containing 0.1 mg 
ZAG in rabbits can induce granulomatous reactions (histiocytes and 
gigantoblasts). 
12. In a large number of tests on human skin, the application of various 
complex preparations and of antiperspirant preparations containing 
between 15.4% and 20% of ZAG, gave rise to a few instances of very 
slight erythema and slight skin dryness in some subjects. No 
sensitization reaction was observed. 
13. The data indicate that ZAG, tested separately and in antiperspirant 
preparations, does not induce granulomatous responses or retarded 
hypersensitivity in subjects previously sensitized to Zr oxide or NaZr 
lactate. 
14. In the USA, antiperspirant products based on ZAG have been on the 
market for over 20 years and the incidence of adverse reactions (skin 
irritation) reported is low (2.4 reactions/10 units sold - 1977-1978). 
Although 70 cases of granulomatous reactions induced by NaZr lactate 
have been reported, and also granulomas induced by application of an 
ointment containing zirconium oxide to the inflamed skin of a woman, no 
reaction of this type has been observed with ZAG. 
15. Consequently, the Committee can approve the use of zirconium/aluminium/ 
glycine complexes as antiperspirants, subject to the conditions and 
restrictions set out in paragraph 1, since the available data and 
observations in human beings offer a sufficient guarantee of safety. 
Nevertheless, the Committee recommends adopting the following warning : 
Do not apply to irritated skin. 
- 22 
ADDITIONAL OPINION OF THE SCIENTIFIC COMMITTEE ON 
COSMETOLOGY CONCERNING THE USE OF BENZOYL PEROXIDE 
(Opinion expressed 17.12.1984) 
Further to item 14 of its Opinion delivered on 29 November 1983, the 
Committee has examined the results of the clinical trials carried out in the 
Federal Republic of Germany on the variation in the threshold of the 
sensitivity of skin to Β ultra-violet rays after short-term application of a 
preparation containing 3% of benzoyl peroxide. 
DISCUSSION 
- These trials clearly showed that the irritant effect of benzoyl peroxide was 
not increased by exposure to UVB radiation at 310 nm but that, on the 
contrary, it depended on the nature of the excipient. 
One case of photo-allergy had been induced in the course of the trials. 
- The Committee still agrees to the use of benzoyl peroxide in lotions, creams 
and gels for greasy skin in a maximum concentration of 3% in the finished 
product, provided that the following warnings appear on the label : 
- Contains benzoyl peroxide. 
- Avoid all contact with the eyes and mouth. 
- Discontinue use if irritation occurs. 
- Other cosmetic products should not be applied simultaneously to 
treated areas. 
- Owing to the effect of the excipient on skin tolerance, the Committee does 
not recommend extending the use of benzoyl peroxide to all products intended 
to improve the condition of skin containing blackheads, and it draws 
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